1. Home
  2. ADTX

as 05-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

Founded: 2017 Country:
United States
United States
Employees: N/A City: RICHMOND
Market Cap: 3.3M IPO Year: 2020
Target Price: $61.00 AVG Volume (30 days): 356.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -65.92 EPS Growth: N/A
52 Week Low/High: $1.95 - $68.08 Next Earning Date: 05-20-2024
Revenue: $506,441 Revenue Growth: -46.23%
Revenue Growth (this year): 95.61% Revenue Growth (next year): 1584.79%

Share on Social Networks: